ReviewInternational journal of molecular sciences2025
Severe Insulin Resistance Syndromes: Clinical Spectrum and Management.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Diabetes Mellitus Is an Independent Predictor of Short-Term Mortality in Critically Ill ICU Patients.Healthcare (Basel, Switzerland) · 2026Article
- TyHGB combined with diagonal earlobe crease and traditional risk factors for constructing a diagnostic model of coronary heart disease.Lipids in health and disease · 2026Article
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Type B insulin resistance with glycemic extremes: a case report and literature review.Frontiers in endocrinology · 2026Review
- Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study.Frontiers in endocrinology · 2026Article
- Structural determinants of non-covalent PPARγ inverse agonism and their therapeutic implications.Nature communications · 2025Article
- Interrelationship Between Dyslipidemia and Hyperuricemia in Patients with Uncontrolled Type 2 Diabetes: Clinical Implications and a Risk Identification Algorithm.Healthcare (Basel, Switzerland) · 2025Article
- The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.Pediatric diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance is a condition wherein cells fail to adequately respond to insulin. It is a prevalent medical condition associated with several diseases, such as type 2 diabetes mellitus, metabolic syndrome, hypertension, obesity, and polycystic ovary syndrome. Insulin resistance may be involved in metabolic disturbances, such as hyperglycemia, hyperinsulinemia, dyslipidemia, hyperuricemia, endothelial dysfunction, elevated inflammatory markers, and a prothrombotic state. Severe insulin resistance syndromes are a heterogeneous group of rare disorders. These disorders are characterized by profound insulin resistance, substantial metabolic abnormalities, and different clinical manifestations and complications. They may be hereditary or acquired, caused by defects in insulin action and cellular responsiveness to insulin. Severe insulin resistance syndromes may also be due to aberrations in adipose tissue function and development. The majority of these disorders are associated with an increased risk of severe complications and mortality. This review aims to summarize the current knowledge on the epidemiology, pathophysiology, complications and prognosis of severe insulin resistance syndromes, as well as to categorize these syndromes by disease process, including defects in insulin receptor, intracellular insulin signaling defects, lipodystrophies, etc.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.